Merck Is Mercury, Schering Is Saturn; Is J&J The Death Star?
This article was originally published in The Pink Sheet Daily
SEC documents reveal Schering-Plough will owe Merck $1.5 billion if their proposed deal collapses. The earthly break-up fee could spur J&J to make a counter-offer.
You may also be interested in...
$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.
A 1998 change-of-control provision tied to Remicade complicates Merck’s attempted mega-merger.
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.